Recently, groundbreaking results were obtained with the administration of PIK3CA inhibitors to patients with CLOVES syndrome, a genetic disorder resulting from somatic gain-of-function variants in PIK3CA [47]. This evidence concerns the gene PIK3CA and hereditary disease.